$DRIO
DarioHealth Corp. Stock $drio

$drio Overview Financials Valuation SEC Filings Company Website

2015 Q4 Form 10-Q Financial Statement

#000114420415064963 Filed on November 13, 2015

Income Statement

Concept	2015 Q4	2015 Q3	2014 Q4
Revenue	$310.0K	$273.0K	$50.00K
YoY Change	520.0%
Cost Of Revenue	$570.0K	$404.0K	$660.0K
YoY Change	-13.64%	-30.94%
Gross Profit	-$260.0K	-$131.0K	-$610.0K
YoY Change	-57.38%	-77.61%
Gross Profit Margin	-83.87%	-47.99%	-1220.0%
Selling, General & Admin	$1.030M	$1.750M	$750.0K
YoY Change	37.33%	52.17%	-60.73%
% of Gross Profit
Research & Development	$570.0K	$667.0K	$730.0K
YoY Change	-21.92%	-13.26%	-58.05%
% of Gross Profit
Depreciation & Amortization	$90.00K	$90.00K	$90.00K
YoY Change	0.0%	-10.0%	-65.38%
% of Gross Profit
Operating Expenses	$1.600M	$2.416M	$1.480M
YoY Change	8.11%	25.7%	-59.45%
Operating Profit	-$1.860M	-$2.547M	-$2.090M
YoY Change	-11.0%	1.6%
Interest Expense	$200.0K	$730.0K	-$970.0K
YoY Change	-120.62%	-71.92%	-126.15%
% of Operating Profit
Other Income/Expense, Net	-$10.00K	$718.0K	-$10.00K
YoY Change	0.0%	-225.96%
Pretax Income	-$1.670M	-$1.830M	-$3.560M
YoY Change	-53.09%	-40.58%	-7220.0%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$1.670M	-$1.829M	-$3.560M
YoY Change	-53.09%	-40.56%	-7220.0%
Net Earnings / Revenue	-538.71%	-669.96%	-7120.0%
Basic Earnings Per Share		-$0.05
Diluted Earnings Per Share	-$12.85M	-$0.05	-$89.00M
COMMON SHARES
Basic Shares Outstanding	42.99M shares	37.43M shares	16.23M shares
Diluted Shares Outstanding		37.43M shares

Balance Sheet

Concept	2015 Q4	2015 Q3	2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.800M	$2.000M	$1.500M
YoY Change	86.67%	-53.49%	-37.5%
Cash & Equivalents	$2.671M	$1.908M	$1.453M
Short-Term Investments	$100.0K	$100.0K	$100.0K
Other Short-Term Assets	$22.00K	$0.00	$33.00K
YoY Change	-33.33%		-36.54%
Inventory	$600.0K	$315.0K	$234.0K
Prepaid Expenses
Receivables	$291.0K		$94.00K
Other Receivables
Total Short-Term Assets	$4.287M	$2.721M	$2.056M
YoY Change	108.51%	-42.45%	-29.83%
LONG-TERM ASSETS
Property, Plant & Equipment	$749.0K	$796.0K	$978.0K
YoY Change	-23.42%	-35.07%	-14.59%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$0.00	$0.00
YoY Change
Total Long-Term Assets	$790.0K	$829.0K	$1.025M
YoY Change	-22.93%	-34.93%	-13.58%
TOTAL ASSETS
Total Short-Term Assets	$4.287M	$2.721M	$2.056M
Total Long-Term Assets	$790.0K	$829.0K	$1.025M
Total Assets	$5.077M	$3.550M	$3.081M
YoY Change	64.78%	-40.85%	-25.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.000M	$900.0K	$700.0K
YoY Change	42.86%	-30.77%	16.67%
Accrued Expenses	$434.0K		$679.0K
YoY Change	-36.08%		14.89%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.690M	$1.500M	$1.616M
YoY Change	4.58%	-28.37%	7.3%
LONG-TERM LIABILITIES
Long-Term Debt	$2.400M	$2.400M	$2.800M
YoY Change	-14.29%	-58.62%
Other Long-Term Liabilities	$2.600M	$3.600M	$4.000M
YoY Change	-35.0%	16.13%	48.15%
Total Long-Term Liabilities	$5.000M	$6.000M	$6.800M
YoY Change	-26.47%	-32.58%	151.85%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.690M	$1.500M	$1.616M
Total Long-Term Liabilities	$5.000M	$6.000M	$6.800M
Total Liabilities	$6.700M	$7.500M	$8.400M
YoY Change	-20.24%	-31.19%	100.0%
SHAREHOLDERS EQUITY
Retained Earnings	-$43.35M	-$41.68M	-$36.06M
YoY Change	20.23%	27.96%	80.26%
Common Stock	$5.000K	$4.000K	$2.000K
YoY Change	150.0%	100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.580M	-$3.960M	-$5.295M
YoY Change
Total Liabilities & Shareholders Equity	$5.077M	$3.550M	$3.081M
YoY Change	64.78%	-40.85%	-25.15%

Cashflow Statement

Concept	2015 Q4	2015 Q3	2014 Q4
OPERATING ACTIVITIES
Net Income	-$1.670M	-$1.829M	-$3.560M
YoY Change	-53.09%	-40.56%	-7220.0%
Depreciation, Depletion And Amortization	$90.00K	$90.00K	$90.00K
YoY Change	0.0%	-10.0%	-65.38%
Cash From Operating Activities	-$2.070M	-$1.380M	-$2.410M
YoY Change	-14.11%	-21.14%	13.15%
INVESTING ACTIVITIES
Capital Expenditures	-$40.00K	-$20.00K	-$340.0K
YoY Change	-88.24%	-71.43%	277.78%
Acquisitions
YoY Change
Other Investing Activities	-$10.00K	$10.00K	$40.00K
YoY Change	-125.0%	-85.71%	-166.67%
Cash From Investing Activities	-$40.00K	-$20.00K	-$300.0K
YoY Change	-86.67%		87.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.880M	2.320M	0.000
YoY Change		-43.41%	-100.0%
NET CHANGE
Cash From Operating Activities	-2.070M	-1.380M	-2.410M
Cash From Investing Activities	-40.00K	-20.00K	-300.0K
Cash From Financing Activities	2.880M	2.320M	0.000
Net Change In Cash	770.0K	920.0K	-2.710M
YoY Change	-128.41%	-60.85%	22.07%
FREE CASH FLOW
Cash From Operating Activities	-$2.070M	-$1.380M	-$2.410M
Capital Expenditures	-$40.00K	-$20.00K	-$340.0K
Free Cash Flow	-$2.030M	-$1.360M	-$2.070M
YoY Change	-1.93%	-19.05%	1.47%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	24000	USD
CY2014Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	4003000	USD
CY2014Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	884000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	2056000	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	667000	USD
CY2015Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-753000	USD
	us-gaap	Revenues Revenues	0	USD
CY2014	drio	Stock Issued During Period Value Upon Exchange Agreement StockIssuedDuringPeriodValueUponExchangeAgreement	4558000	USD
CY2015Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q3	us-gaap	Stockholders Equity StockholdersEquity	-3960000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	-5295000	USD
CY2014Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	47000	USD
CY2015Q3	us-gaap	Short Term Investments ShortTermInvestments	69000	USD
CY2015Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	419000	USD
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3081000	USD
CY2015Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	2357000	USD
CY2014Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	2757000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	234000	USD
CY2015Q3	us-gaap	Inventory Net InventoryNet	315000	USD
CY2015Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	54000	USD
CY2015Q3	us-gaap	Assets Current AssetsCurrent	2721000	USD
CY2015Q3	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	594000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	978000	USD
CY2015Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	3626000	USD
CY2015Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	37718000	USD
CY2015Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	796000	USD
CY2015Q3	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2015Q3	us-gaap	Assets Assets	3550000	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	2000	USD
CY2015Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	33000	USD
CY2015Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3550000	USD
CY2014Q4	us-gaap	Assets Assets	3081000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	30761000	USD
CY2014Q4	us-gaap	Short Term Investments ShortTermInvestments	83000	USD
CY2015Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-41682000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-36058000	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	286000	USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	1922000	USD
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1332000	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2507000	USD
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-35000	USD
CY2015Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	718000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-1829000	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	2416000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	1611000	USD
	us-gaap	Gross Profit GrossProfit	-1611000	USD
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	901000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2547000	USD
CY2014Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3176000	USD
CY2014Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-570000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-3077000	USD
CY2014Q3	us-gaap	Revenues Revenues	0	USD
CY2015Q3	us-gaap	Revenues Revenues	273000	USD
CY2014Q3	us-gaap	Cost Of Revenue CostOfRevenue	585000	USD
CY2015Q3	us-gaap	Cost Of Revenue CostOfRevenue	404000	USD
CY2014Q3	us-gaap	Gross Profit GrossProfit	-585000	USD
CY2015Q3	us-gaap	Gross Profit GrossProfit	-131000	USD
CY2014Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2606000	USD
	us-gaap	Revenues Revenues	515000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	1111000	USD
	us-gaap	Gross Profit GrossProfit	-596000	USD
	us-gaap	Operating Expenses OperatingExpenses	5240000	USD
	us-gaap	Operating Expenses OperatingExpenses	7167000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-377000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-3144000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-11000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3681000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	366000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-537000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-5470000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-9315000	USD
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1829000	USD
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6333000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5624000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12571000	USD
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2014Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.66
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.03
CY2015Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37433188	shares
CY2014Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9610160	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29835891	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6179981	shares
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2014Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.66
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.23
CY2015Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37433188	shares
CY2014Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9610160	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29835891	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6194418	shares
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-86000	USD
CY2014	drio	Deemed Dividend Related To Exchange Agreement Adjustment DeemedDividendRelatedToExchangeAgreementAdjustment	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	70000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	219000	USD
CY2015Q3	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	283000	USD
CY2014	drio	Deemed Dividend Related To Preferred Stock DeemedDividendRelatedToPreferredStock	0	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	400000	USD
CY2014	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	46000	USD
CY2014	drio	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	352000	USD
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	768000	USD
CY2014	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1692000	USD
	drio	Stock Issued During Period Value New Issues April And May2013 StockIssuedDuringPeriodValueNewIssuesAprilAndMay2013	1956000	USD
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	2325000	USD
	drio	Deemed Dividend Inducement Of Warrant Exercise In May2015 DeemedDividendInducementOfWarrantExerciseInMay2015	0	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4214000	USD
	us-gaap	Payments For Proceeds From Loans Receivable PaymentsForProceedsFromLoansReceivable	-333000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	30000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	81000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	109000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	330000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	130000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	8000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-65000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-125000	USD
	drio	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	1956000	USD
	drio	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	3754000	USD
	drio	Proceeds From Stock Options And Warrants Exercised ProceedsFromStockOptionsAndWarrantsExercised	350000	USD
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	2325000	USD
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	4734000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	8200000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	455000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1907000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2263000	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4170000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	26000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	323000	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	0	USD
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	9000	USD
CY2014Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	68000	USD
CY2015Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	32000	USD
CY2014Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	166000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	138000	USD
CY2014	us-gaap	Inventory Write Down InventoryWriteDown	1046000	USD
	drio	Bank Charges BankCharges	13000	USD
	drio	Bank Charges BankCharges	17000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-11000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	6000	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	533000	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	0	USD
CY2015Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	160000000	shares
	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	6052	shares
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	768000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1522000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	8326634	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	6000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	157775	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	98225	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	8.05
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.14
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1317400	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9382034	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	8730371	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3311443	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.59
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.01
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1.05
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.12
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	8000	USD
CY2015Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	14000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P9M22D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y1M24D
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y11M23D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y14D
CY2015Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	1270000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y1M28D
CY2015Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1923636	shares
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	453000	USD
CY2015Q3	drio	Stock Issued During Period Warrants Exercised StockIssuedDuringPeriodWarrantsExercised	1923636	shares
CY2015Q2	drio	Deemed Dividend Inducement Of Warrant Exercise In May2015 DeemedDividendInducementOfWarrantExerciseInMay2015	154000	USD
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2015-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Registrant Name EntityRegistrantName	LabStyle Innovations Corp.
	dei	Entity Central Index Key EntityCentralIndexKey	0001533998
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Trading Symbol TradingSymbol	DRIO
CY2015Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	42993162	shares
CY2015Q3	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent	10000	USD
CY2014Q4	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent	0	USD
CY2015Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2015Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42768309	shares
CY2015Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	42768309	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16233430	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16233430	shares
CY2015Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2015Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	4940000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	4940000	shares
CY2015Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	USD
CY2014Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	2977000	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	2977000	USD
CY2015Q3	drio	Deemed Dividend Related To Exchange Agreement DeemedDividendRelatedToExchangeAgreement	0	USD
CY2014Q3	drio	Deemed Dividend Related To Exchange Agreement DeemedDividendRelatedToExchangeAgreement	279000	USD
	drio	Deemed Dividend Related To Exchange Agreement DeemedDividendRelatedToExchangeAgreement	0	USD
	drio	Deemed Dividend Related To Exchange Agreement DeemedDividendRelatedToExchangeAgreement	279000	USD
CY2015Q3	drio	Deemed Dividend Related To Warrants Exchange Agreement DeemedDividendRelatedToWarrantsExchangeAgreement	0	USD
CY2014Q3	drio	Deemed Dividend Related To Warrants Exchange Agreement DeemedDividendRelatedToWarrantsExchangeAgreement	0	USD
	drio	Deemed Dividend Related To Warrants Exchange Agreement DeemedDividendRelatedToWarrantsExchangeAgreement	154000	USD
	drio	Deemed Dividend Related To Warrants Exchange Agreement DeemedDividendRelatedToWarrantsExchangeAgreement	0	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	10000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
	us-gaap	Payments To Acquire Leases Held For Investment PaymentsToAcquireLeasesHeldForInvestment	-12000	USD
	us-gaap	Payments To Acquire Leases Held For Investment PaymentsToAcquireLeasesHeldForInvestment	6000	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	0	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	4096000	USD
	drio	Payment For Executives And Directors Under Salary Program PaymentForExecutivesAndDirectorsUnderSalaryProgram	232000	USD
	drio	Payment For Executives And Directors Under Salary Program PaymentForExecutivesAndDirectorsUnderSalaryProgram	0	USD
	drio	Consideration Granted To Investors From Exchange Agreement ConsiderationGrantedToInvestorsFromExchangeAgreement	0	USD
	drio	Consideration Granted To Investors From Exchange Agreement ConsiderationGrantedToInvestorsFromExchangeAgreement	3124000	USD
	drio	Proceeds From Exercise Of Warrants Into Common Stock ProceedsFromExerciseOfWarrantsIntoCommonStock	453000	USD
	drio	Proceeds From Exercise Of Warrants Into Common Stock ProceedsFromExerciseOfWarrantsIntoCommonStock	0	USD
	drio	Proceeds From Stock Options And Warrants Exercised ProceedsFromStockOptionsAndWarrantsExercised	0	USD
	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0%"></td> <td style="TEXT-ALIGN: left; WIDTH: 56pt"> <div>NOTE 3:-</div> </td> <td style="TEXT-ALIGN: justify"> <div>UNAUDITED INTERIM FINANCIAL STATEMENTS</div> </td> </tr> </table>   <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 56.7pt" align="justify"><font style="FONT-SIZE: 10pt">The accompanying unaudited interim consolidated financial statements as of September 30, 2015, have been prepared in accordance with U.S. generally accepted accounting principles and standards of the Public Company Accounting Oversight Board for interim financial information. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles in the United States for complete financial statements. In the opinion of management, the unaudited interim consolidated financial statements include all adjustments of a normal recurring nature necessary for a fair presentation of the Company's consolidated financial position as of September 30, 2015, and the Company's consolidated results of operations and the Company's consolidated cash flows for the nine months ended September 30, 2015. Results for the nine months ended September 30, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015.</font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0	USD
CY2014	drio	Stock Issued During Period Value New Issues February2014 StockIssuedDuringPeriodValueNewIssuesFebruary2014	1013000	USD
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.32
	drio	Compensation To Investors From Exchange Agreement CompensationToInvestorsFromExchangeAgreement	0	USD
	drio	Compensation To Investors From Exchange Agreement CompensationToInvestorsFromExchangeAgreement	3124000	USD
	drio	Issuance Of Common Stock In April And August2015 To Service Provider IssuanceOfCommonStockInAprilAndAugust2015ToServiceProvider	64000	USD
	drio	Issuance Of Common Stock In September2015 To Employees IssuanceOfCommonStockInSeptember2015ToEmployees	591000	USD
	drio	Issuance Of Common Stock In September2015 To Service Provider IssuanceOfCommonStockInSeptember2015ToServiceProvider	16000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	232000	USD
	drio	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	453000	USD
CY2014	drio	Issuance Of Common Stock In February And March2012 IssuanceOfCommonStockInFebruaryAndMarch2012	2.75
	drio	Issuance Of Common Stock And Warrants In February And June2013 IssuanceOfCommonStockAndWarrantsInFebruaryAndJune2013	0.18
	us-gaap	Revenue Recognition Software RevenueRecognitionSoftware	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 56.7pt" align="justify"></div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 58.5pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="78"> <div><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="36"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">a.</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Revenue recognition:</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 85.5pt" align="justify"><font style="FONT-SIZE: 10pt">Revenues from product sales are recognized in accordance with Accounting Standard Codification ("ASC") 605-10 “Revenue Recognition”, when delivery has occurred, persuasive evidence of an agreement exists, the vendor’s fee is fixed or determinable, no further obligation exists and collectability is probable.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 112.5pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 85.05pt" align="justify"><font style="FONT-SIZE: 10pt">The Company derives revenues from the sale of its Dario Smart Meter and its related device-specific disposables test strip cartridges and lancets through independent distributers or directly to end users. The Dario software application is offered for a free download and the Company does not obtain a recurring hosting commitment towards the end users relating specifically to the application.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 85.5pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 85.05pt" align="justify"><font style="FONT-SIZE: 10pt">The Company generally has a standard contract with its distributors. According to the agreements, all sales to distributors are final, no rights of return or price protection right is granted to such distributors and the Company is not a party of the agreements between distributors and their customers.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 85.05pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 85.05pt" align="justify"><font style="FONT-SIZE: 10pt">Through September 30, 2015, product sales to distributors are recognized as revenues upon receipt of payment. The Company will apply this policy until it will have sufficient historical experience with each distributor in order to conclude that fee is fixed or determinable and collectability is probable.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 112.5pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 85.5pt" align="justify"><font style="FONT-SIZE: 10pt">The Company also generates revenues from arrangements with health care providers which include supply of Dario Smart Meters and software platform that requires certain customization followed by monthly service, support and maintenance.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 85.05pt" align="justify"><font style="FONT-SIZE: 10pt">When a sales arrangement contains multiple elements, such as software and non-software components, the Company allocates revenue to each element based on a selling price hierarchy as required according to ASC 605-25, “Multiple-Element Arrangements”. The selling price for a deliverable is based on its Vendor Specific Objective Evidence (“VSOE”), if available, third party evidence (“TPE”) if VSOE is not available, or estimated selling price (“ESP”) if neither VSOE nor TPE is available. The best estimate of selling price is established considering several internal factors including, but not limited to, historical sales, pricing practices and geographies in which the Company offers its products. The determination of ESP is judgmental.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 85.05pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 85.05pt" align="justify"><font style="FONT-SIZE: 10pt">Revenues from software components in sales arrangement contains multiple elements are recognized when all criteria outlined in ASC 985-605, “Software Revenue Recognition” (“ASC 985-605”), are met. Revenue from services is recognized when persuasive evidence of an arrangement exists, delivery of the product has occurred or the services have been rendered, the fee is fixed or determinable and collectability is probable.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">  </font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 85.05pt" align="justify"><font style="FONT-SIZE: 10pt">For multiple element arrangements within ASC 985-605, revenues are allocated to the different elements in the arrangement under the “residual method” when VSOE of fair value exist for all undelivered elements and no VSOE exists for the delivered elements. Under the residual method, at the outset of the arrangement with the customer, the fair value of the undelivered elements is deferred and the remaining portion of the arrangement fee is allocated to the delivered elements and is recognized as revenue when the basic criteria in ASC 985-605 have been met. Any discount in the arrangement is allocated to the delivered element.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 85.05pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 85.05pt" align="justify"><font style="FONT-SIZE: 10pt">Since VSOE does not exist for undelivered elements, revenues are recognized as one unit of accounting, on a straight-line basis over the term of the last deliverable based on ASC 605-15, “Products” and ASC 985-605.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 85.05pt" align="justify"><font style="FONT-SIZE: 10pt">Deferred revenues include advances and payments received from customers, for which revenue has not yet been recognized.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 28.35pt; MARGIN: 0in 0in 0pt 56.7pt" align="justify"><font style="FONT-SIZE: 10pt">The Company’s shipping and handling costs are included in cost of revenues.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0	USD

Files In Submission

Name	View Source	Status
0001144204-15-064963-index-headers.html	Edgar Link	pending
0001144204-15-064963-index.html	Edgar Link	pending
0001144204-15-064963.txt	Edgar Link	pending
0001144204-15-064963-xbrl.zip	Edgar Link	pending
drio-20150930.xml	Edgar Link	completed
drio-20150930.xsd	Edgar Link	pending
drio-20150930_cal.xml	Edgar Link	unprocessable
drio-20150930_def.xml	Edgar Link	unprocessable
drio-20150930_lab.xml	Edgar Link	unprocessable
drio-20150930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v423961_10q.htm	Edgar Link	pending
v423961_ex31-1.htm	Edgar Link	pending
v423961_ex31-2.htm	Edgar Link	pending
v423961_ex32-1.htm	Edgar Link	pending
v423961_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DRIO
DarioHealth Corp. Stock $drio

2015 Q4 Form 10-Q Financial Statement

#000114420415064963 Filed on November 13, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DRIO DarioHealth Corp. Stock $drio

2015 Q4 Form 10-Q Financial Statement

#000114420415064963 Filed on November 13, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DRIO
DarioHealth Corp. Stock $drio